-
EP4299589
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4299589
| EP4299589 - ANTI-HUMAN CD73 ANTIBODY AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 01.12.2023 Database last updated on 18.03.2026 | |
| Former | The international publication has been made Status updated on 03.09.2022 | Most recent event Tooltip | 26.11.2025 | Amendment by applicant | Applicant(s) | For all designated states Novoprotein Scientific Inc. Floor 3&4, No.228 Yunchuang Road Wujiang Economic Development Zone Suzhou, Jiangsu 215200 / CN | For all designated states Novoprotein Scientific (Shanghai) Inc. Floor 3, Building 1 No.11 Jialilue Road, China (Shanghai) Pilot Free Trade Zone Pudong New Area Shanghai 201203 / CN | [N/P] |
| Former [2024/01] | For all designated states Novoprotein Scientififc Inc. Floor 3&4, No.228 Yunchuang Road Wujiang Economic Development Zone Suzhou, Jiangsu 215200 / CN | ||
| For all designated states Novoprotein Scientific (Shanghai) Inc. Floor 3, Building 1 No.11 Jialilue Road, China (Shanghai) Pilot Free Trade Zone Pudong New Area Shanghai 201203 / CN | Inventor(s) | 01 /
LI, Debin Suzhou, Jiangsu 215200 / CN | 02 /
SONG, Zuowei Suzhou, Jiangsu 215200 / CN | 03 /
LU, Na Suzhou, Jiangsu 215200 / CN | 04 /
YU, Futao Shanghai 201203 / CN | [2024/01] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [2024/01] | Application number, filing date | 21927468.5 | 16.07.2021 | [2024/01] | WO2021CN106917 | Priority number, date | CN202110202193 | 24.02.2021 Original published format: CN202110202193 | CN202110292998 | 18.03.2021 Original published format: CN202110292998 | [2024/01] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022179039 | Date: | 01.09.2022 | Language: | ZH | [2022/35] | Type: | A1 Application with search report | No.: | EP4299589 | Date: | 03.01.2024 | Language: | EN | [2024/01] | Search report(s) | International search report - published on: | CN | 01.09.2022 | (Supplementary) European search report - dispatched on: | EP | 12.05.2025 | Classification | IPC: | C07K16/28, C07K19/00, C12N15/13, C12N5/10, A61K39/395, A61K39/00, A61K47/68, A61P35/00, A61P35/02, G01N33/68 | [2024/01] | CPC: |
C07K16/2896 (EP,US);
A61K40/10 (EP,US);
A61K40/4271 (EP,US);
A61K47/6813 (US);
A61K47/6815 (US);
A61K47/6849 (US);
A61K51/1027 (US);
A61P35/00 (EP,US);
C07K14/4702 (EP);
C07K14/7051 (US);
G01N33/573 (EP);
G01N33/68 (US);
A61K2239/57 (EP,US);
C07K2317/24 (EP,US);
C07K2317/622 (US);
C07K2317/73 (EP);
C07K2317/76 (EP);
C07K2317/77 (EP);
C07K2317/80 (EP);
C07K2317/92 (EP);
G01N2333/70596 (US);
G01N2333/916 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/01] | Title | German: | ANTI-HUMAN-CD73-ANTIKÖRPER UND VERWENDUNG DAVON | [2024/01] | English: | ANTI-HUMAN CD73 ANTIBODY AND USE THEREOF | [2024/01] | French: | ANTICORPS ANTI-CD73 HUMAIN ET SON UTILISATION | [2024/01] | Entry into regional phase | 25.09.2023 | Translation filed | 25.09.2023 | National basic fee paid | 25.09.2023 | Search fee paid | 25.09.2023 | Designation fee(s) paid | 25.09.2023 | Examination fee paid | Examination procedure | 25.09.2023 | Examination requested [2024/01] | 25.11.2025 | Amendment by applicant (claims and/or description) | 25.11.2025 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 25.09.2023 | Renewal fee patent year 03 | 25.07.2024 | Renewal fee patent year 04 | 28.07.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [PX] CN112552406 (WUJIANG NOVOPROTEIN SCIENT INC et al.) [PX] 1-14 * paragraphs [0009] - [0083]; examples 1-6; sequences 6,7 * | [I] WO2020143836 (SHANGHAI PHARMAEXPLORER CO LTD et al.) [I] 1-14 * paragraphs [0008] - [0186] * | [I] US2021024646 (YU KE et al.) [I] 1-14 * paragraphs [0007] - [0203] * | [I] US2019352418 (WILSON NICHOLAS STUART et al.) [I] 1-14 * paragraphs [0007] - [0097] - [0501] - [0515] * | [I] WO2019232244 (NOVARTIS AG et al.) [I] 1-14 * page 2, line 5 - page 9, line 17 * | [I] WO2019170131 (UNIV FUDAN et al.) [I] 1-14 * paragraphs [0007] - [0210] * |